Hepatitis Studies Shyam Kottilil M.D., Ph.D.

Slides:

Advertisements

Similar presentations

Changes in How We Die Most deaths now in institutions –Families less able to care for dying patients Most deaths due to chronic illness Dying usually takes.

Advertisements

HIV/HCV Coinfection News – HCV Protease Inhibitors

Chapter 7 EM Math Probability.

Artrelle Fragher & Robert walker. 1 you look for the median 1 you look for the median 2 then you look for the min and max 2 then you look for the min.

Breast Cancer Patient Issues in Family Practice: An Interactive Session.

Fill in missing numbers or operations

Name: Date: Read temperatures on a thermometer Independent / Some adult support / A lot of adult support

$1 Million $500,000 $250,000 $125,000 $64,000 $32,000 $16,000 $8,000 $4,000 $2,000 $1,000 $500 $300 $200 $100 Welcome.

CirculatingTumor Cells: Toward a clinical benefit? Giuseppe Naso MD, PhD, Associated Professor of Medical Oncology Director of Traslational Oncology Paola.

Ozone Level ppb (parts per billion)

Multiplication X 1 1 x 1 = 1 2 x 1 = 2 3 x 1 = 3 4 x 1 = 4 5 x 1 = 5 6 x 1 = 6 7 x 1 = 7 8 x 1 = 8 9 x 1 = 9 10 x 1 = x 1 = x 1 = 12 X 2 1.

Division ÷ 1 1 ÷ 1 = 1 2 ÷ 1 = 2 3 ÷ 1 = 3 4 ÷ 1 = 4 5 ÷ 1 = 5 6 ÷ 1 = 6 7 ÷ 1 = 7 8 ÷ 1 = 8 9 ÷ 1 = 9 10 ÷ 1 = ÷ 1 = ÷ 1 = 12 ÷ 2 2 ÷ 2 =

Durability of Response and Rate of Re-emergence of Wild Type at Boceprevir (BOC) Resistance-Associated Variant (RAV) Loci in Genotype 1a and 1b Patients:

Adherence to Hepatitis C Therapies and The Impact of Comorbid Conditions Mary Cassler RPh, MBA, Lon Castle, M.D., Bill Dreitlein, Pharm.D., Mona Khalid,

Adherence to HCV Therapy: Relation with Virologic Outcomes and Changes in Adherence Over Time Vincent Lo Re, MD, MSCE V. Teal, R. Localio, V. Amorosa,

How many people do we need to vaccinate?. Suppose R 0 = 10 How many new infections result from each infected person on average? 10 So how many people.

HIV/AIDS in Argentina Vanesa Fridman, MD Infectious Disease Hospital de Clinicas Universidad de Buenos Aires, Argentina.

EACS COURSE Aix-en-Provence Sep Ireland Dublin Capital City.

Ministry of Health National STD/AIDS Programme Universal Access to Antiretroviral Therapy: The Brazilian Experience.

Statistics & Declining HCV infections Mark Stoové, PhD Centre for Epidemiology & Population Health Research (CEPHR) Burnet Institute.

/4/2010 Box and Whisker Plots Objective: Learn how to read and draw box and whisker plots Starter: Order these numbers.

AS. 02/03 Finding fractions of a quantity AS. 02/03.

Number Theory Click to begin. Click here for Final Jeopardy.

DiseaseNo disease 60 people with disease 40 people without disease Total population = 100.

Who Wants To Be A Millionaire?

Who Wants To Be A Millionaire?

£1 Million £500,000 £250,000 £125,000 £64,000 £32,000 £16,000 £8,000 £4,000 £2,000 £1,000 £500 £300 £200 £100 Welcome.

The challenge of harnessing the demographic dividend

Optimal therapy in genotype 1 patients 3 rd Paris Hepatitis Conference January 2009 Stefan Zeuzem, MD J.W. Goethe University Hospital Frankfurt,

$100 $200 $300 $400 $100 $200 $300 $400 $100 $200 $300 $400 $100 $200 $300 $400 $100 $200 $300 $400.

Least Common Multiple (LCM)

Price Points With Bar Charts. Investment to Value Ratio $45,000 - $65,000 $25,000 - $45,000 Under $25,000 $90,000 - $125,000 $65,000 - $90,000 Low Price.

Core epidemiological slides HIV/AIDS estimates

Let’s Play Who Wants to be a Millionaire! Lifelines Phone a friend, 50/50, Ask the audience.

Access to Health Care in Africa : Laboratory Diagnostics Cape Town, April 16 –

Hepatitis C The next generation of Treatment for Hepatitis C.

Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality (AHRQ)

Elasticity and its Application

National Institute for Public Health and the Environment HIV, HCV, and HBV in injecting drug users in Europe Mirjam Kretzschmar Centre for Infectious Disease.

How accurate is your view of the world?. 1. What is the population of the world? a. 3 billionb. 5 billion c. 7 billiond. 9 billion.

Washington State Department of Health April 14, 2010 Washington State Cohort Review 2009 trends & 1 st quarter.

Number bonds to 10,

Hepatitis B Virus. Hepatitis B - Clinical Features Incubation period:Average days Range days Clinical illness (jaundice):

Fractions Simplify: 36/48 = 36/48 = ¾ 125/225 = 125/225 = 25/45 = 5/9

Management of non naïve patients with hepatitis C "Non-Responders" 3rd Paris Hepatitis Conference, Paris, Christoph Sarrazin J. W. Goethe-University.

IDENTIFICATION OF FACTORS IMPACTING THE DETERMINATION OF HIV INCIDENCE IN NON-RESEARCH-BASED, CLINICAL POPULATIONS Sill, A.M. 1 ; Constantine, N.T. 2 ;

Kyle bought a bike from his friend. His friend gave him a 20% discount. He paid $40 for it. How much was the original price of the bike?

HIV and Aging Kathleen K Casey, MD Director, AIDS Ambulatory Care Center Jersey Shore University Medical Center.

When, how and which patient to treat with HBV infection. David Mutimer Queen Elizabeth Hospital Birmingham, England. BSG Post-graduate Course March 20.

Washington D.C., USA, July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin + Peginterferon in Genotypes 1-3 PROTON Phase 2 Treatment Naïve Lawitz E, et al. Lancet.

N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER CROI 2015: What’s New in Hepatitis? Nina Kim, MD Associate Professor of Medicine Division of Allergy &

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.

Hepatitis web study Hepatitis web study Peginterferon alfa-2a + RBV versus Interferon alfa-2a + RBV ACTG 5071 Phase 2 Treatment Naïve, Chronic HCV and.

Hepatitis web study Hepatitis web study Simeprevir in HIV Coinfection, GT-1 C212 Trial Phase 3 Treatment Naïve and Treatment Experienced Dieterich D, et.

Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.

Slide 1 of 5 From SC Ray, MD, at Chicago, IL: May 20, 2013, IAS-USA. IAS–USA Stuart C. Ray, MD, FIDSA Professor of Medicine and Oncology Director, Infectious.

Management of Patients Co- infected with HCV and HIV: A Close Look at the Role for DAAs Susanna Naggie, MD Assistant Professor of Medicine Division of.

Changing Epidemiology of Opportunistic Infections in the HAART Era International AIDS Society 2012 Henry Masur MD Chief, Critical Care Medicine Department.

Update on Genetic Links to HCV Clearance Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE.

ELPA Symposium Compassionate Use in Hepatitis C Saving lives of patients who cannot wait Thomas Berg Section of Hepatology Clinic for Gastroenterology.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIH SYNERGY Phase 2 Treatment Naïve (unfavorable baseline.

Abstract MOAB0301 Hepatitis C Care Cascade for People Living With HIV in the Country of Georgia Nikoloz Chkhartishvili1, A. Abutidze1, N. Bolokadze1, O.

Hepatitis C Incidence and Prevalence in the U.S.

Effect of highly active anti-retroviral therapy and hepatitis C virus co-infection on serum levels of pro-inflammatory and immunoregulatory cytokines.

Simeprevir in HIV Coinfection, GT-1 C212 Trial

Hepatitis C in the HIV-infected patient

Presentation transcript:

Hepatitis Studies Shyam Kottilil M.D., Ph.D. Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Bethesda, MD

Hepatitis C and HIV coexist in the US IVDU 5 100 HCV 90% 4 80 3 60 Number affected (millions) Percentage All HIV+ 2 40 33% HIV 1 20 Population Population Sulkowski MS, Mast EE, Seeff, LB et al. Hepatitis C Virus Infection as an Opportunistic Disease in Persons infected with Human Immunodeficiency Virus. Clin Infect Dis. 2000;30:577-84.

Washington, D.C. Our Nation’s Capital 3%=18000 HIV+ 1.8%=12000 HCV+ 3

Numbers found below each ward refer to the rate of newly reported Establishment of Hepatitis Clinics Average Incidence Rate per 100,000 Population 0 - 25.0 25.1 – 50.0 50.1 – 75.0 75.1 – 100.0 100.1 – 125.0 Numbers found below each ward refer to the rate of newly reported HIV cases per 100,000 population. Rates were calculated using 2000 Census data. For 16% of cases, ward information was not available and therefore not displayed on this map. 4

Hepatitis Treatment Protocols-DC-PFAP TLR7 Phase 1 HCV-DAA Natural History GS-7977+RBV Anti-fibrosis Anti-fibrosis HCV DAA Tx Jan June Sept June Mar Dec Mar Sept Anti-fibrosis Peg+RBV+PI (Boc) IFN and RBV FREE Tx TLR7 PHASE 1 HCV-DAA

Most Effective HIV Program Most Effective Hepatitis Program Washington, D.C. Our Nation’s Capital Most Effective HIV Program Most Effective Hepatitis Program 6